NCT02210819 (XALIA LEA) is a clinical trial of Rivaroxaban (Xarelto, BAY59-7939) in Deep Vein Thrombosis (DVT), sponsored by Bayer.

Who is sponsoring NCT02210819?

NCT02210819 is sponsored by Bayer.

What drugs are being tested in NCT02210819?

Interventions in NCT02210819: Rivaroxaban (Xarelto, BAY59-7939), Recommended VTE pharmacological treatments according to international guidelines.

What condition does NCT02210819 study?

NCT02210819 studies Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE).

Is NCT02210819 still recruiting?

NCT02210819 is currently completed. Last updated 29 August 2019.

Last reviewed 2019-08-29 · How we verify

NCT02210819: XALIA LEA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

Completed Last updated 29 August 2019

What this trial tests

trial testing Rivaroxaban (Xarelto, BAY59-7939) in Deep Vein Thrombosis (DVT) in 1,987 participants. Completed in 20 January 2017.

Timeline

27 June 2014

Primary endpoint
3 November 2016

20 January 2017

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,987
Start date	27 June 2014
Primary completion	3 November 2016
Estimated completion	20 January 2017
Sites	21 locations across Jordan, Malaysia, Kazakhstan, Taiwan, South Korea, Philippines, Qatar, Lebanon

Drugs / interventions tested

Rivaroxaban (Xarelto, BAY59-7939) — full drug profile →
Recommended VTE pharmacological treatments according to international guidelines — full drug profile →

Conditions studied

Deep Vein Thrombosis (DVT) — all drugs for Deep Vein Thrombosis (DVT) →
Pulmonary Embolism (PE) — all drugs for Pulmonary Embolism (PE) →

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute venous thoromboembolism (VTE). The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute VTE in routine clinical practice.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.
Haas S, Mantovani LG, Kreutz R, Monje D, et al · · 2021 · cited 11× · PMID 33870028 · DOI 10.1002/rth2.12489

Verify or expand the search:

Other trials of Rivaroxaban (Xarelto, BAY59-7939)

Trials testing the same drug.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT06193863 — An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Hea · active not recruiting
NCT05461807 — An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to · completed
NCT05150938 — A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE) · completed
NCT04923139 — A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Datab · completed

Other recruiting trials for Deep Vein Thrombosis (DVT)

Currently open trials in the same condition.

NCT06909240 — Progressive Gait Training After First-time Deep Venous Thrombosis: Clinical Effectiveness and Involved Mecanisms (The DV · NA · recruiting
NCT07439991 — Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02210819 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 29 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02210819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing